Article Details
Retrieved on: 2024-06-04 19:42:43
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the survival benefits of durvalumab in treating limited-stage small-cell lung cancer, a major focus in the biopharma industry. The key biopharmaceutical companies involved in related research and development include Amgen, G1 Therapeutics, Novartis, Roche, and Eli Lilly and Company.
Article found on: www.healio.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here